Patrizia Chiusolo
A5042424261- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Blood Coagulation and Thrombosis Mechanisms
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Venous Thromboembolism Diagnosis and Management
- Cytomegalovirus and herpesvirus research
- Retinoids in leukemia and cellular processes
- Immune Cell Function and Interaction
- Folate and B Vitamins Research
- Hematological disorders and diagnostics
- Transplantation: Methods and Outcomes
- Platelet Disorders and Treatments
- Kruppel-like factors research
Agostino Gemelli University Polyclinic
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
1998-2025
Università Cattolica del Sacro Cuore
2016-2025
Catholic University of America
2001-2025
Advanced Radiation Therapy (United States)
2024
Istituto di Ematologia di Bologna
1998-2024
Pontifícia Universidade Católica de São Paulo
2011-2024
Weatherford College
2024
University of Brescia
2016-2023
European Institute of Oncology
2016
Point mutations in the factor V gene (factor Leiden) and prothrombin (the substitution of A for G at position 20210) are most common causes inherited thrombophilia. Whether or not Leiden increases risk recurrent deep venous thrombosis is controversial, there no information on recurrence among carriers both mutations.
Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve prediction of clinical outcome currently available tool (Revised [IPSS-R]). We aimed provide an extensive validation IPSS-M.
Despite advances in graft-versus-host-disease (GVHD) treatment, it is estimated that overall survival (OS) at 2 years for hematopoietic cell transplantation (HCT) recipients who experience steroid-resistant GVHD 10%. Among recent therapeutic approaches mesenchymal stromal cells (MSCs) hold a key position. We describe multicenter of 11 pediatric patients diagnosed with acute or chronic (aGVHD, cGVHD) treated compassionate use GMP-grade unrelated HLA-disparate donors' bone marrow-derived MSCs,...
Epidemiologic investigation of invasive fungal diseases (IFDs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be useful to identify subpopulations who might benefit from targeted treatment strategies. The Gruppo Italiano Trapianto Midollo Osseo (GITMO) prospectively registered data on 1858 consecutive patients undergoing allo-HSCT between 2008 and 2010. Logistic regression analysis was performed risk factors for proven/probable IFD (PP-IFD) during the early (days 0...
A low count of CD4+ and CD8+ lymphocytes is a hallmark laboratory finding in the coronavirus disease 2019 (COVID-19). Using flow cytometry, we observed significantly higher CD95 (Fas) PD-1 expression on both T cells 42 COVID-19 patients when compared to controls. Higher correlated with lower counts. percentage naive events. Our results might suggest shift antigen-activated cells, expressing molecules increasing their propensity apoptosis exhaustion during infection.
Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) leading causes of morbidity mortality. In this regard, impact JAK2V617F variant allele frequency (VAF) is still debated. The purpose current study was to analyze VAF context other established risk factors for thrombosis a total 865 2016 WHO-defined PV utilizing two independent cohorts: University Florence (n = 576) as training cohort Policlinico Gemelli, Catholic...
Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal (PMBCL); however, only few PMBCLs were reported. Aim was to evaluate and safety of axicabtagene in patients with PMBCL compared those other LBCL, enrolled the Italian prospective observational CART-SIE study. (n = 70) younger, higher percentage bulky refractory disease, LBCLs 190). Median follow-up time infused 12.17 months (IQR 5.53,22.73). The overall (complete +...
Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating benefits and risks of HSCT MDS, timing being a crucial question. Here, we aimed to develop validate decision support system define optimal MDS on basis clinical genomic information as provided by Molecular International Prognostic Scoring System (IPSS-M).
Background Dimethyl sulfoxide ( DMSO ) is essential for the preservation of liquid nitrogen–frozen stem cells, but associated with toxicity in transplant recipient. Study Design and Methods In this prospective noninterventional study, we describe use 64 E uropean B lood M arrow T ransplant G roup centers undertaking autologous transplantation on patients myeloma lymphoma analyze side effects after return ‐preserved cells. Results While majority continue to 10% , a significant proportion...
To shed light onto the molecular basis of Philadelphia chromosome-positive acute lymphoblastic leukemia and to investigate prognostic role additional genomic lesions, we analyzed copy number aberrations using Cytoscan HD Array in 116 newly diagnosed adult patients with enrolled four different GIMEMA protocols, all based on a chemotherapy-free induction strategy. This analysis showed that carry an average 7.8 lesions/case, deletions outnumbering gains (88% versus 12%). The most common were...
CD4+ and CD8+ chimeric antigen receptor T cells (CAR-T) play different roles in the vivo anti-tumour response, but role of /CD8+ ratio among infused CAR-T has not been clearly defined yet. We analysed leftovers from anti-CD19 bags 31 patients with aggressive B-cell lymphomas. The median was 1.44, lower for brexu-cel compared to tisa-cel axi-cel. CAR+CD4+ influenced by lactate dehydrogenase levels at apheresis, age, previous treatments or peripheral blood. Patients a response 3 months after...